New drug MCAM takes first step toward fighting opioid addiction

NCT ID NCT07602335

Not yet recruiting Disease control Sponsor: The University of Texas Health Science Center at San Antonio Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial will test the safety and blood levels of an investigational drug called MCAM in 24 healthy adults. Participants will receive a single dose of MCAM or a placebo and be monitored for 8 days. The goal is to find the highest safe dose for future studies on opioid use disorder.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MCAM (an investigational drug taken by mouth)
What this could lead to: If this early safety trial succeeds, it could pave the way for a new medication to help control opioid use disorder.
What could go wrong: This is a very early Phase 1 trial with only 24 healthy participants, so it is not designed to test effectiveness. The drug may cause side effects or fail to show benefit in later studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPIOID-USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPIOID-USE DISORDER

Contacts and locations

Locations

Dr. Vince Clinical Research

Overland Park, Kansas, 66212, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.